Merck KGaA to Acquire Sigma-Aldrich for Approx. $17 billion (€13.1 billion)
Merck KGaA (Darmstadt, Germany) has announced that it has entered into an agreement to acquire Sigma-Aldrich (Kansas City, Missouri, USA) for approximately $17 billion (€13.1 billion).
Merck KGaA (Darmstadt, Germany) has announced that it has entered into an agreement to acquire Sigma-Aldrich (Kansas City, Missouri, USA) for approximately $17 billion (€13.1 billion). As a result of the acquisition, the Life Science contribution to Merck KGaA’s earnings will more than double, and will expand the company’s reach in North America.
Merck KGaA report that the Sigma-Aldrich Board of Directors has unanimously approved the transaction, and a merger agreement will be presented to Sigma-Aldrich shareholders for approval. Closing is expected in mid-2015, subject to regulatory approvals and other conditions.
Karl-Ludwig Kley, chairman of Merck KGaA’s Executive Board, commented that the two companies fit perfectly together and will be able to offer a much broader range of products to their customers in research, pharmaceutical and biopharmaceutical manufacturing, and diagnostic and testing laboratories. “The combination of Merck and Sigma-Aldrich will secure stable growth and profitability in an industry that is driven by trends such as the globalization of research and manufacturing,” he said.
Rakesh Sachdev, president and chief executive officer of Sigma-Aldrich, touted the acquisition as a testament to the Sigma-Aldrich brand and the accomplishments of the company’s 9000 employees worldwide. “This transaction is a clear validation of our success in transforming Sigma-Aldrich into a customer-focused and solutions-oriented global organization,” he said.
The life sciences division of Merck KGaA is known as EMD Millipore in the United States and as Merck Millpore in the rest of the world.
The Complexity of Oligonucleotide Separations
January 9th 2025Peter Pellegrinelli, Applications Specialist at Advanced Materials Technology (AMT) explains the complexity of oligonucleotide separations due to the unique chemical properties of these molecules. Issues such as varying length, sequence complexity, and hydrophilic-hydrophobic characteristics make efficient separations difficult. Separation scientists are addressing these challenges by modifying mobile phase compositions, using varying ion-pairing reagents, and exploring alternative separation modes like HILIC and ion-exchange chromatography. Due to these complexities, AMT has introduced the HALO OLIGO column, which offers high-resolution, fast separations through its innovative Fused-Core® technology and high pH stability. Alongside explaining the new column, Peter looks to the future of these separations and what is next to come.
Frontage Laboratories Streamlines their Product Lifecycle Management with NuGenesis™ LMS
January 9th 2025Frontage laboratories wanted to improve the efficiency and quality of their operations and invest in ways to streamline their workflows. They implemented Waters NuGenesis™ Lab Management System (LMS) to progress their digital transformation journey and combine synergistic data, workflow, and sample management capabilities to support the entire product lifecycle from discovery through manufacturing.
The Intricacies of Oligonucleotide Separations
January 9th 2025Peter Pellegrinelli, Applications Specialist at Advanced Materials Technology (AMT) explains the complexity of oligonucleotide separations due to the unique chemical properties of these molecules. Issues such as varying length, sequence complexity, and hydrophilic-hydrophobic characteristics make efficient separations difficult. Separation scientists are addressing these challenges by modifying mobile phase compositions, using varying ion-pairing reagents, and exploring alternative separation modes like HILIC and ion-exchange chromatography. Due to these complexities, AMT has introduced the HALO OLIGO column, which offers high-resolution, fast separations through its innovative Fused-Core® technology and high pH stability. Alongside explaining the new column, Peter looks to the future of these separations and what is next to come.
